Anthem BioSciences

Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Pvt. Ltd.)
49, F1 & F2, Canara Bank Road,
Bommasandra Industrial Area, Phase - I
Bommasandra. Bengaluru - 560 099
Karnataka, India
CIN : L24233KA2006PLC039703
Tel : + 91 80 6672 4000
www.anthembio.com

Date: July 21, 2026

To,

BSE Limited,	National Stock Exchange of India Limited
20th Floor, P.J. Towers,	Exchange Plaza, C-1, Block G,
Dalal Street,	Bandra Kurla Complex, Bandra (E),
Mumbai - 400001.	Mumbai – 400 051
BSE Scrip Code: 544449	NSE Scrip Symbol: ANTHEM

Subject: Revised Earnings Call Presentation of the Company Pertaining to the quarter ended June 30, 2026

Dear Sir/Ma'am

With reference to our earlier letter dated July 21, 2026, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the Earnings Call Presentation on the Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026, we wish to inform you that the Company has revised the said Earnings Call Presentation.

Accordingly, please find enclosed herewith the revised Earnings Call Presentation. The revised presentation supersedes and replaces the presentation submitted earlier.

The same is also available on the Company's website at https://anthembio.com/.

We request you to kindly take the same on record.

Thanking you,

Yours truly,
For Anthem Biosciences Limited
(*Formerly known as Anthem Biosciences Private Limited*)

DIVYA PRASAD
Digitally signed by DIVYA PRASAD
Date: 2026.07.21 19:09:27 +05'30'

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

Anthem Biosciences Limited

Investor Presentation

July 21, 2026

Safe Harbour

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute “forward-looking statements”. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Consolidated Profit & Loss Statement: Q1FY27 vs Q1FY26 vs Q4FY26 Performance

Particulars (₹ Mn)	Q1FY27	Q1FY26	YoY	Q4FY26	QoQ	FY26
Revenue from Operations	4,182	5,402	***-22.6%***	**6,109**	***-31.5%***	**21,243**
CRDMO	3,408	4,527	*-24.7%*	5,128	*-33.5%*	17,727
Specialty Ingredients	774	875	*-11.5%*	981	*-21.1%*	3,516
Other Income	249	228	*9.2%*	512	*-51.4%*	1,558
Total Revenues	**4,431**	**5,630**	***-21.3%***	**6,622**	***-33.1%***	**22,801**
Cost of materials consumed and changes in inventories	1,462	2,309	*-36.7%*	2,155	*-32.2%*	8,123
Employee benefits expense	788	720	*9.5%*	725	*8.7%*	2,827
Other expenses	426	458	*-7.0%*	558	*-23.6%*	1,955
EBITDA	**1,755**	**2,143**	***-18.1%***	**3,184**	***-44.9%***	**9,896**
EBITDA Margins	**39.6%**	***38.1%***	***153 bps***	**48.1%**	***(849 bps)***	***43.4%***
Finance cost	9	16	*-44.5%*	19	*-53.3%*	69
Depreciation and amortization expense	300	264	*13.6%*	396	*-24.3%*	1,341
PBT before exceptional items	**1,446**	**1,862**	***-22.4%***	**2,769**	***-47.8%***	**8,486**
Exceptional Items*	*n.a.*	*n.a.*	*n.a.*	(10)	*n.a.*	244
PBT after exceptional items	**1,446**	**1,862**	***-22.4%***	**2,779**	***-48.0%***	**8,242**
Total tax expense	246	505	*-51.2%*	882	*-72.1%*	2,324
Profit after tax	**1,199**	**1,358**	***-11.7%***	**1,898**	***-36.8%***	**5,918**

Anthem® BioSciences

Q1FY27 Consolidated Financial Highlights

Revenues (₹ Mn)



EBITDA[1] (₹ Mn) and EBITDA Margins (%age)



PAT (₹ Mn) and PAT Margins (%age)





PBT (₹ Mn) and PBT Margins (%age)



Net Cash (₹ Mn)



Note:

1. EBITDA for Q1FY27 includes Other Income of INR 249 Mn (Other Operating Income o/a of forex gain (net) and RoDTEP incentive is INR 13 Mn and Financial / Non Operating Income is INR 236 Mn). Corresponding figures for Q1FY26 was Other Income of INR 228 Mn (Other Operating Income o/a of forex gain (net) and RoDTEP incentive was INR 37 Mn and Financial / Non Operating Income was INR 191 Mn)

Margin profile continues to remain strong for Q1FY27

Strong Business Performance	**₹4,182 Mn** Q1FY27 Revenues	**39.6%** Q1FY27 EBITDA Margin	**27.1%** Q1FY27 PAT Margin
Robust Technology and Infrastructure	**14 + 10** Commercial + Late Stage (Phase III) Molecules	**425KL** Custom Synthesis Capacity	**142KL** Fermentation Capacity
Strong Returns and Balance Sheet	**15.4% / 23.3%** ROE / Q1FY27 Post Tax ROCE	**1.10x** Q1FY27 Gross Fixed Assets Turnover	**2.45x** Net Cash / Q1FY27 EBITDA*

*Based on Annualised EBITDA

Financial Highlights: Q1FY27

Quarter Performance:

- Consolidated Revenue from Operations was ₹4,182 Mn for the quarter
  - CRDMO business delivered ₹3,408 Mn revenues
  - Specialty Ingredients delivered ₹774 Mn revenues
- EBITDA was ₹1,755 Mn, with EBITDA margins at 39.6%
- PAT (Profit After Tax) was ₹1,199 Mn, with PAT margins at 27.1%
- Net Cash position as of June 30, 2026 is ₹17,197 Mn

Message from Chairman, MD and CEO

AJAY BHARDWAJ
Chairman, MD & CEO

"Our Q1FY27 quarterly results reflect timing shifts in deliveries to key customers. The underlying demand remains strong, and with a higher concentration of scheduled deliveries in the latter half of the year, we are positioned to capture that momentum. We remain firmly committed to sustaining revenue growth aligned with our long-term historical performance.

On the margin front, we delivered year-on-year improvement across both EBITDA and PAT margins. Our disciplined focus on cost efficiencies, yield optimisation, and employee productivity continues to reinforce our industry-leading margin profile, positioning us to sustain this performance through the year".

Thank You

Anthem Biosciences Limited

Unit I: No.49, F1 &F2, Canara Bank Road, Bommasandra Industrial Area Phase 1, Bommasandra, Bangalore, 560 099, India

Unit II: Plot No 276-P & 277-P, Survey No-20, Harohalli Industrial Area, Phase II, Near Bannikuppe Village, Kanakapura Taluk, Ramnagar District, Harohalli, Karnataka 562112, India

NeoAnthem Lifesciences Private Limited

Unit III: 313-P,314-P, 318-P, Harohalli Industrial Area, Phase II, Kanakapura Taluk, Ramnagar District, Harohalli, Karnataka, 562112, India

For further information please contact
investors.abl@anthembio.com or anthem@adfactorspr.com